SynthesisFrontiers in aging neuroscience2022
A Bibliometric Review on Gut Microbiome and Alzheimer's Disease Between 2012 and 2021.
Synthesis in Frontiers in aging neuroscience, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 24 citations in OpenAlex.
- Research Hotspots and Frontiers of Alzheimer's Disease and Gut Microbiota: A Knowledge Mapping and Text Mining Analysis.Molecular neurobiology · 2024Article
- Review
- Global landscape of COVID-19 research: a visualization analysis of randomized clinical trials.Clinical and experimental medicine · 2024Article
- Rheumatic diseases and gut microbiota publications in 2002-2022: a Scopus‑based bibliometric analysis.Rheumatology international · 2023Article
- Gut microbiota and autism spectrum disorders: where do we stand?Gut pathogens · 2023Article
- Unveiling the hidden world of gut health: Exploring cutting-edge research through visualizing randomized controlled trials on the gut microbiota.World journal of clinical cases · 2023Article
- Bibliometric mapping of the landscape and structure of nutrition and depression research: visualization analysis.Journal of health, population, and nutrition · 2023Article
- Integrin β3-Mediated Cell Senescence Associates with Gut Inflammation and Intestinal Degeneration in Models of Alzheimer's Disease.International journal of molecular sciences · 2023Article
- Emerging Trends and Focus in Human Skin Microbiome Over the Last Decade: A Bibliometric Analysis and Literature Review.Clinical, cosmetic and investigational dermatology · 2023Article
- Editorial: The effect of gut microbiota on the brain structure and function.Frontiers in integrative neuroscience · 2023Article
- A Bibliometric Review onBioMed research international · 2023Review
- Trends of mitochondrial changes in AD: a bibliometric study.Frontiers in aging neuroscience · 2023Article
- A bibliometric review on vitamins and Alzheimer's disease between 1996 and 2023.Frontiers in aging neuroscience · 2023Article
- Effects of human probiotics on memory and psychological and physical measures in community-dwelling older adults with normal and mildly impaired cognition: results of a bi-center, double-blind, randomized, and placebo-controlled clinical trial (CleverAge biota).Frontiers in aging neuroscience · 2023Article
- Bibliometric analysis of research on Alzheimer's disease and non-coding RNAs: Opportunities and challenges.Frontiers in aging neuroscience · 2022Article
- Brain-gut axis and psychiatric disorders: A perspective from bibliometric and visual analysis.Frontiers in immunology · 2022Article
- A bibliometric analysis of studies on the gut microbiota in cardiovascular disease from 2004 to 2022.Frontiers in cellular and infection microbiology · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Research on the microbiome has drawn an increasing amount of attention over the past decade. Even more so for its association with disease. Neurodegenerative diseases, such as Alzheimer's disease (AD) have been a subject of study for a long time with slow success in improving diagnostic accuracy or identifying a possibility for treatment. In this work, we analyze past and current research on microbiome and its positive impact on AD treatment and diagnosis. We present a bibliometric analysis from 2012 to 2021 with data retrieved on September 2, 2021, from the Scopus database. The query includes "Gut AND (Microbiota OR Microbiome) AND Alzheimer*" within the article title, abstract, and keywords for all kinds of documents in the database. Compared with 2016, the number of publications (NPs) on the subject doubled by 2017. Moreover, we observe an exponential growth through 2020, and with the data presented, it is almost certain that it will continue this trend and grow even further in the upcoming years. We identify key journals interested in the subject and discuss the articles with most citations, analyzing trends and topics for future research, such as the ability to diagnose the disease and complement the cognitive test with other clinical biomarkers. According to the test, mild cognitive impairment (MCI) is normally considered an initial stage for AD. This test, combined with the role of the gut microbiome in early stages of the disease, may improve the diagnostic accuracy. Based on our findings, there is emerging evidence that microbiota, perhaps more specifically gut microbiota, plays a key role in the pathogenesis of diseases, such as AD.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.